Regulatory Update

Weekly Regulatory News

September 2024 brings several medical device regulatory developments in Singapore, new ASEAN classification guidance in Malaysia, imminent UDI implementation in Colombia, and more.

Published on:
September 10, 2024

SINGAPORE

New Consultation: Guidance on Change Management Program (CMP) for SaMD

The Medical Devices Cluster (MDC) has released a draft guidance document for the Change Management Program (CMP) specifically for Software as a Medical Device (SaMD). This guidance outlines regulatory requirements and the process for submitting CMPs, offering a new optional pathway within HSA's Premarket Product Registration and Change Notification (CN) systems. It also introduces the concept of pre-specified changes. Stakeholders are invited to provide their feedback on the draft during the consultation period from 26 August 2024 to 21 October 2024.

NextGen MD Initiative: Streamlined Registration for Next-Generation Medical Devices

The NextGen MD Initiative simplifies the registration process for next-generation medical devices, allowing applicants to leverage previously submitted data. This initiative applies to Class B, C, and D devices (excluding MD-drug combinations) and focuses on enhancing the registration efficiency for devices with similar characteristics to their predecessors.

Eligibility: Next-gen devices must share the same product type, validation data (biocompatibility, sterilization, and shelf-life), and other identical criteria compared to the registered device. Only devices registered via the FULL or ABRIDGED route are eligible.

How to Apply: Submit the "NextGen MD Form" along with the regular registration to hsa_md_info@hsa.gov.sg, referencing the job application number.

Effective Date: This opt-in initiative starts on 1 July 2024.

Regulatory Updates for Therapeutic Product Registration (Effective 1 Aug 2024)

The Health Sciences Authority (HSA) has introduced several key updates aimed at improving regulatory efficiency and clarity for therapeutic product registration, effective from 1 August 2024.

Key changes include:

  1. New Evaluation Milestone Tool: A tool to estimate key evaluation timelines for NDA, GDA, and MAV-1 applications.
  2. Cloud-Based Submission (EasiShare): A new option for dossier submission through EasiShare, alongside existing methods.
  3. Post-Approval Change Guidelines: A list of changes that no longer require notification to HSA, including product labelling changes for e-labelling.
  4. Patent Declaration Updates: Changes in the Health Products Regulations with revised patent forms now available.
  5. Swissmedic as a Reference Agency: Swissmedic is added as a reference agency for product evaluation.

Additional updates:

  • GMP compliance requirements for chemical drug substance manufacturers will be mandatory from 1 October 2024.
  • Implementation timelines for the eCTD platform have been extended, with regular progress updates.

Learn more about HSA Singapore Medical Device Registration.

MALAYSIA

MDA Updates ASEAN Medical Device Classification Guidance

The Malaysian Medical Device Authority (MDA) has released revised guidance on classifying medical devices under the ASEAN Medical Device Directive (AMDD). This update standardizes classification across ASEAN countries, helping manufacturers and authorized representatives comply with regional regulations.

Key points:

  • Devices are classified from Class A (low-risk) to Class D (high-risk).
  • Includes detailed annexes for specific device classifications.
  • Annual updates ensure alignment with the latest regulatory and technological changes.

Learn more about MDA Malaysia Medical Device Registration.

COLOMBIA

Colombia to Implement Unique Device Identifier (UDI) for Medical Devices and IVDs Starting 2024 Updated: Aug 24, 2023

Colombia is set to implement the Unique Device Identifier (UDI) system for medical devices (MDs) and in-vitro diagnostics (IVDs) beginning in 2024. The UDI system ensures clear identification and traceability of devices on the market.

Key deadlines:

  • By Feb 8, 2024: UDI-DI must be provided for Class III MDs and IVDs.
  • By Aug 8, 2025: UDI-DI must be submitted for Class IIb MDs and Class II IVDs.
  • By Feb 8, 2026: UDI-DI for Class IIa, Class I MDs, and Class I IVDs.

Learn more about INVIMA Colombia Medical Device Registration.

CANADA

Medical Device Reports and Publications

Medical devices, as defined by the Food and Drugs Act, include a range of health instruments for treatment, diagnosis, and disease prevention. Access reports and publications related to medical devices here.

Request reports:

  • For quarterly (2020-2024) or annual (2018-2024) reports, email: publications@hc-sc.gc.ca.
  • For more information, contact the Medical Devices Directorate at: meddevices-instrumentsmed@hc-sc.gc.ca.

Learn more about CDMR Canada Medical Device Registration & Approval.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

Regulatory Update
December 18, 2024

Closing out 2024, we bring you substantial medical device updates from Europe, Brazil, and beyond, including the launch of public consultation on EU device regulations, an updated roadmap for regulatory implementations in the UK, and several new and updated resolutions in Brazil.

Regulatory Update
December 11, 2024

Early December 2024 regulatory news brings updates from Europe, US, Brazil, China, and Japan, including new FDA guidance on change controls for AI-enabled devices and an innovation-focused approach to clinical research regulations in Brazil.

An extensive round-up of medical device regulatory news from November 2024 includes new and updated guidance documents, Q&As, and directives from Europe and the US, including the new EU Product Liability Directive for AI and Smart Products.

Pure Global is proud to announce its inclusion in the China Business Service Providers (BSP) directory on the International Trade Administration website.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Pure Global 2024 Year in Review
Blog Article
Pure Global 2024 Year in Review

As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.

Blog Article
EU Parliament Revises MDR and IVDR

On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.

Blog Article
Language Challenges in MedTech Going Global and Our Solution

Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.